Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Combinations or Ceralasertib Monotherapy in Metastatic Triple-Negative Breast Cancer
NCT03801369Phase 2Terminated
- Start
- Dec 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and ceralasertib in triple-negative breast cancer (TNBC) (4 arms). Primary endpoint: Objective Response Rate up to 24 months. Started Dec 2018; status: terminated.
02
Drugs
olaparibceralasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03801369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801369.